- Home
- INMB vs PCM Comparison
INMB vs PCM Comparison
Compare INMB & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INMB | PCM |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 66.8M |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | INMB | PCM |
|---|---|---|
| Price | $2.03 | $4.96 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 315.2K | 101.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $4.90 |
| 52 Week High | $2.60 | $6.76 |
Technical Indicators
Market Signals| Indicator | INMB | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 26.65 |
| Support Level | $1.97 | $4.95 |
| Resistance Level | $2.17 | $5.83 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 15.15 | 15.91 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.